CELLTRION, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 172,900 KRW | -2.37% |
|
-5.10% | -14.19% |
| Apr. 17 | Celltrion, Inc. announces an Equity Buyback for 436,047 shares. | CI |
| Apr. 17 | Celltrion, Inc. authorizes a Buyback Plan. | CI |
| Sales 2024 * | 3,428B 2.5B | Sales 2025 * | 4,172B 3.04B | Capitalization | 35,838B 26.09B |
|---|---|---|---|---|---|
| Net income 2024 * | 505B 368M | Net income 2025 * | 1,099B 800M | EV / Sales 2024 * | 10.6 x |
| Net Debt 2024 * | 656B 477M | Net Debt 2025 * | 297B 216M | EV / Sales 2025 * | 8.66 x |
| P/E ratio 2024 * |
69.3
x | P/E ratio 2025 * |
32.2
x | Employees | 2,034 |
| Yield 2024 * |
0.24% | Yield 2025 * |
0.25% | Free-Float | 63.67% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
More news
| 1 day | -2.37% | ||
| 1 week | -5.10% | ||
| Current month | -9.57% | ||
| 1 month | -6.24% | ||
| 3 months | -1.76% | ||
| 6 months | +21.50% | ||
| Current year | -14.19% |
1 week
169 700.00
180 800.00
1 month
169 700.00194 100.00
Current year
169 700.00241 000.00
1 year
131 000.00241 000.00
3 years
131 000.00283 276.77
5 years
121 026.29372 915.00
10 years
27 751.54372 915.00
| Managers | Title | Age | Since |
|---|---|---|---|
Wu-Sung Ki
CEO | Chief Executive Officer | 62 | 07-04-23 |
Ho-Seop Lee
DFI | Director of Finance/CFO | 49 | - |
Jung-Jin Seo
CHM | Chairman | 66 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Soon-Woo Lee
BRD | Director/Board Member | 73 | - |
Jung-Jin Seo
CHM | Chairman | 66 | - |
Jong-Seok Lee
BRD | Director/Board Member | 72 | 14-12-07 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 4.14% | 2 M€ | -14.14% | ||
| 0.99% | 11 M€ | -.--% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 172,900 | -2.37% | 504,100 |
| 24-04-18 | 177,100 | +3.57% | 474,859 |
| 24-04-17 | 171,000 | -0.58% | 686,492 |
| 24-04-16 | 172,000 | -3.70% | 635,729 |
| 24-04-15 | 178,600 | -1.98% | 362,320 |
End-of-day quote Korea S.E., April 18, 2024
More quotes
Celltrion Inc is a Korea-based company mainly engaged in the production and sale of bio pharmaceuticals. The Company operates its business through two segments. The Bio Pharmaceutical segment produces and sells protein therapeutics such as anticancer drugs. In addition, this Segment develops monoclonal antibodies(mABs) that are used to treat chronic autoimmune diseases such as arthritis and severe diseases such as breast and colon cancer. The Chemical Pharmaceutical segment is mainly engaged in the manufacture and sale of chemical drugs. In addition, the Segment sells bio drugs, and provides services such as data analysis. The Company's main products include liver and bowel medicines and other generics. The main products sold by the Company include autoimmune disease treatment agents, anti-malignant tumor drugs and other products. The Company sells its products in domestic and overseas markets such as Europe and the United States.
Calendar
2024-05-07
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
172,900
KRW
Average target price
227,765
KRW
Spread / Average Target
+31.73%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -14.19% | 26.05B | |
| -1.42% | 41.52B | |
| +42.15% | 39.9B | |
| +1.97% | 38.83B | |
| +1.82% | 23.78B | |
| -24.55% | 18.26B | |
| -4.07% | 11.65B | |
| +21.36% | 11.53B | |
| +8.20% | 11.2B | |
| -19.49% | 9.76B |
- Stock Market
- Equities
- A068270 Stock
